176 related articles for article (PubMed ID: 37798436)
21. Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma.
Zuo N; Ma L; Liu T; Hu W; Luo Y; Meng H; Ren Q; Deng Y; Wei L; Liu Q
Oral Oncol; 2023 May; 140():106367. PubMed ID: 36996606
[TBL] [Abstract][Full Text] [Related]
22. Predictive Role of ERCC1 Expression in Head and Neck Squamous Cell Carcinoma Patients Treated with Surgery and Adjuvant Cisplatin-Based Chemoradiation.
Ciaparrone M; Caspiani O; Bicciolo G; Signorelli D; Simonelli I; de Campora L; Mazzarella G; Mecozzi A; Pianelli C; Camaioni A; Catalano P; Pasqualetti P; Fabiano A; Radici M; Marmiroli L; Corsi DC
Oncology; 2015; 89(4):227-34. PubMed ID: 26066774
[TBL] [Abstract][Full Text] [Related]
23. Metastases of squamous cell carcinoma of the head and neck show increased levels of nucleotide excision repair protein XPF in vivo that correlate with increased chemoresistance ex vivo.
Köberle B; Ditz C; Kausch I; Wollenberg B; Ferris RL; Albers AE
Int J Oncol; 2010 May; 36(5):1277-84. PubMed ID: 20372803
[TBL] [Abstract][Full Text] [Related]
24. Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine.
Mlak R; Krawczyk P; Homa-Mlak I; Powrózek T; Ciesielka M; Kozioł P; Milanowski J; Małecka-Massalska T
Pathol Oncol Res; 2019 Jul; 25(3):1035-1045. PubMed ID: 30066234
[TBL] [Abstract][Full Text] [Related]
25. CYP1A1, GSTM1 and GSTT1 polymorphisms, tobacco and alcohol status and risk of head and neck squamous cell carcinoma.
Lourenço GJ; Silva EF; Rinck-Junior JA; Chone CT; Lima CS
Tumour Biol; 2011 Dec; 32(6):1209-15. PubMed ID: 21870186
[TBL] [Abstract][Full Text] [Related]
26. Gene-environment interaction and susceptibility in head and neck cancer patients and in their first-degree relatives: a study of Northeast Indian population.
Choudhury JH; Ghosh SK
J Oral Pathol Med; 2015 Aug; 44(7):495-501. PubMed ID: 25167831
[TBL] [Abstract][Full Text] [Related]
27. Association of GSTP1 and ERCC1 polymorphisms with toxicity in locally advanced head and neck cancer platinum-based chemoradiotherapy treatment.
Duran G; Aguín S; Cruz R; Barros F; Giráldez JM; Bernárdez B; López-López R; Carracedo Á; Lamas MJ
Head Neck; 2019 Aug; 41(8):2704-2715. PubMed ID: 30973677
[TBL] [Abstract][Full Text] [Related]
28. High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area.
Chiu TJ; Chen CH; Chien CY; Li SH; Tsai HT; Chen YJ
J Transl Med; 2011 Mar; 9():31. PubMed ID: 21426588
[TBL] [Abstract][Full Text] [Related]
29. cRGD peptide installation on cisplatin-loaded nanomedicines enhances efficacy against locally advanced head and neck squamous cell carcinoma bearing cancer stem-like cells.
Miyano K; Cabral H; Miura Y; Matsumoto Y; Mochida Y; Kinoh H; Iwata C; Nagano O; Saya H; Nishiyama N; Kataoka K; Yamasoba T
J Control Release; 2017 Sep; 261():275-286. PubMed ID: 28666729
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial.
Zheng Y; Dou H; Li Q; Sun Y; Wang Y; Zhang W
Cancer Control; 2021; 28():1073274821997444. PubMed ID: 34029149
[TBL] [Abstract][Full Text] [Related]
31. nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.
Johnson KCC; Ley J; Oppelt P; Lu J; Gay HA; Daly M; Jackson R; Rich J; Pipkorn P; Paniello RC; Zevallos J; Thorstad W; Adkins DR
Med Oncol; 2019 Oct; 36(11):93. PubMed ID: 31595355
[TBL] [Abstract][Full Text] [Related]
32. Head and neck squamous-cell cancer and its association with polymorphic enzymes of xenobiotic metabolism and repair.
Harth V; Schafer M; Abel J; Maintz L; Neuhaus T; Besuden M; Primke R; Wilkesmann A; Thier R; Vetter H; Ko YD; Bruning T; Bolt HM; Ickstadt K
J Toxicol Environ Health A; 2008; 71(13-14):887-97. PubMed ID: 18569591
[TBL] [Abstract][Full Text] [Related]
33. Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy.
Cabelguenne A; Loriot MA; Stucker I; Blons H; Koum-Besson E; Brasnu D; Beaune P; Laccourreye O; Laurent-Puig P; De Waziers I
Int J Cancer; 2001 Sep; 93(5):725-30. PubMed ID: 11477586
[TBL] [Abstract][Full Text] [Related]
34. Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience.
Cavalieri S; Platini F; Barretta F; Nuzzolese I; Ottini A; Bergamini C; Resteghini C; Colombo E; Iacovelli NA; Franceschini M; Calareso G; Di Pede P; De Feo G; Gandelli M; Toffolatti L; Guglielmo M; Ripamonti CI; Cosmai L; Licitra L; Alfieri S
Oral Oncol; 2023 Nov; 146():106579. PubMed ID: 37778228
[TBL] [Abstract][Full Text] [Related]
35. Multi-Omics Identification of Genetic Alterations in Head and Neck Squamous Cell Carcinoma and Therapeutic Efficacy of HNC018 as a Novel Multi-Target Agent for c-MET/STAT3/AKT Signaling Axis.
Khedkar HN; Chen LC; Kuo YC; Wu ATH; Huang HS
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373393
[TBL] [Abstract][Full Text] [Related]
36. Proteins and single nucleotide polymorphisms involved in apoptosis, growth control, and DNA repair predict cisplatin sensitivity in head and neck cancer cell lines.
Farnebo L; Jedlinski A; Ansell A; Vainikka L; Thunell LK; Grénman R; Johansson AC; Roberg K
Int J Mol Med; 2009 Oct; 24(4):549-56. PubMed ID: 19724896
[TBL] [Abstract][Full Text] [Related]
37. Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck.
Jeremic B; Milicic B; Dagovic A; Vaskovic Z; Tadic L
J Clin Oncol; 2004 Sep; 22(17):3540-8. PubMed ID: 15337803
[TBL] [Abstract][Full Text] [Related]
38. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
[TBL] [Abstract][Full Text] [Related]
39. Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition.
Liao J; Yang Z; Carter-Cooper B; Chang ET; Choi EY; Kallakury B; Liu X; Lapidus RG; Cullen KJ; Dan H
Clin Exp Metastasis; 2020 Apr; 37(2):283-292. PubMed ID: 32020377
[TBL] [Abstract][Full Text] [Related]
40. Association of genetic polymorphisms in glutathione S-transferases and susceptibility to head and neck cancer.
Singh M; Shah PP; Singh AP; Ruwali M; Mathur N; Pant MC; Parmar D
Mutat Res; 2008 Feb; 638(1-2):184-94. PubMed ID: 18035380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
